Literature DB >> 28293770

The value of "en toto" globe submission in the assessment of high-risk retinoblastoma cases and staging.

Hind Manaa Alkatan1, Hani ALBalawi2, Azza M Y Maktabi3.   

Abstract

PURPOSE: To evaluate the importance of "en toto" globe submission in the assessment of high-risk pathological findings in retinoblastoma cases, aiming at identifying the additional value from full globe examination of enucleated eyes (including the calottes).
METHODS: Retrospective histopathological case series of eighty-one enucleated globes with the clinical diagnosis of retinoblastoma, histopathologically examined at King Khaled Eye Specialist Hospital (KKESH) between January 2010 and December 2013. We included retinoblastoma eyes with any type of invasion (more than pT1) in which the globe was submitted "en toto." All cases were histopathologically classified according to the American Joint Cancer Classification (AJCC TNM classification, 2009 6th edition).
RESULTS: 81 enucleated globes were examined, out of which 30 globes were classified as high-risk cases (more than pT1). 8 cases had massive choroidal invasion in both the PO sections and calottes. 5 cases had focal choroidal invasion in both. One case has massive choroidal invasion in calottes with very superficial ON head invasion. Two cases were found to have focal choroidal invasion in the calottes with prelaminar ON invasion. In these three cases (10%), the presence of focal or massive choroidal invasion in the calottes has affected the classification.
CONCLUSIONS: This study consolidates the guidelines recommended in the consensus meeting: from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination and evaluation of prognostic risk factors in retinoblastoma eyes. Full globe submission and examination should be the routine accepted practice universally even in underdeveloped countries.

Entities:  

Keywords:  Histopathology; Retinoblastoma; Tumor classification

Mesh:

Year:  2017        PMID: 28293770     DOI: 10.1007/s10792-016-0410-5

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  21 in total

1.  The evaluation and current concept of retinoblastoma therapy.

Authors:  A B REESE; R M ELLSWORTH
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1963 Mar-Apr

Review 2.  Intraocular retinoblastoma: the case for a new group classification.

Authors:  A Linn Murphree
Journal:  Ophthalmol Clin North Am       Date:  2005-03

3.  Bilateral retinoblastoma with ectopic intracranial retinoblastoma: trilateral retinoblastoma.

Authors:  J L Bader; A T Meadows; L E Zimmerman; L B Rorke; P A Voute; L A Champion; R W Miller
Journal:  Cancer Genet Cytogenet       Date:  1982-03

4.  Incidence of retinoblastoma in the USA: 1975-2004.

Authors:  E Broaddus; A Topham; A D Singh
Journal:  Br J Ophthalmol       Date:  2008-07-11       Impact factor: 4.638

Review 5.  Historic review of retinoblastoma.

Authors:  D M Albert
Journal:  Ophthalmology       Date:  1987-06       Impact factor: 12.079

6.  Trilateral retinoblastoma. Report of two cases.

Authors:  S Brownstein; J P de Chadarévian; J M Little
Journal:  Arch Ophthalmol       Date:  1984-02

7.  Postenucleation adjuvant therapy in high-risk retinoblastoma.

Authors:  Santosh G Honavar; Arun D Singh; Carol L Shields; Anna T Meadows; Hakan Demirci; Jacqueline Cater; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2002-07

8.  Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments.

Authors:  Julia Balaguer; Matthew W Wilson; Catherine A Billups; John Mancini; Barrett G Haik; Ibrahim Qaddoumi; Joseph D Khoury; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

9.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.

Authors:  S H Friend; R Bernards; S Rogelj; R A Weinberg; J M Rapaport; D M Albert; T P Dryja
Journal:  Nature       Date:  1986 Oct 16-22       Impact factor: 49.962

10.  Retinoma: spontaneous regression of retinoblastoma or benign manifestation of the mutation?

Authors:  B L Gallie; R M Ellsworth; D H Abramson; R A Phillips
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.